Background. We evaluated a new vaccine, Mic1-3KO, against both chronic and congenital toxoplasmosis in mice. Mic1-3KO is a mutant strain of Toxoplasma gondii RH that lacks the mic1 and mic3 genes.
mental retardation [1] [2] [3] . Congenital toxoplasmosis is also of considerable economic importance in the livestock industry, because it is one of the principal causes of abortion, fetal death, and stillbirths in sheep and goats.
Primary Toxoplasma infection leads to an immune response that confers lifelong protection against reinfection and against the congenital transmission of toxoplasmosis. Therefore, it should be possible to develop a safe and effective vaccine against acquired and congenital toxoplasmosis. A vaccine based on live attenuated S48 Toxoplasma tachyzoites is available, and it can protect pregnant sheep against toxoplasmosis [4] . However, with a naturally attenuated vaccine such as this, the possibility exists that it might at some point revert to a pathogenic form, which makes it a poor vaccine candidate for humans. Futhermore, if the challenge is of sufficien severity, it will not provide total protection. Futhermore, the attenuated S48 vaccine is difficul to manufacture and has a short shelf life. Cytokine production by splenocytes from female Swiss OF1 mice vaccinated with Mic1-3KO. Splenocytes were recovered 2 months after vaccination and were stimulated in vitro with Toxoplasma gondii antigen (5 mg/mL). Cell-free supernatants were harvested and assayed for interleukin (IL)-2 and IL-4 activity after 24 h, for IL-10 activity after 72 h, and for interferon (IFN)-g activity after 96 h.
for IFN-g, IL-2, and IL-10; P ! .001 P ! for IL-4. .14 A mutant strain of T. gondii RH that lacks carbamoyl phosphate synthetase II (uracil auxotroph) has been constructed and is completely avirulent not only in immunocompetent mice but also in those that lack interferon (IFN)-g [5] . A single injection of this mutant strain into BALB/c mice induced longterm protective immunity against intraperitoneal (ip) challenge with RH tachyzoites. One strategy for developing safer vaccines against toxoplasmosis is, thus, to create specifi gene-deficien strains of T. gondii. For example, a new mutant strain of T. gondii RH that lacks the mic1 and mic3 genes (the Mic1-3 knockout [KO] parasite) was created. During early invasion, T. gondii secretes proteins from micronemes-specialized organelles located at the apical end of the parasite that play a central role in the recognition of and adhesion to host cells [6, 7] . Microneme proteins (MICs) contain adhesive motifs and, in some cases, bind to putative receptors on host cells. Twelve MICs have been identified and the host-cell surface binding properties of 2 (MIC1 and MIC3) have been demonstrated [8, 9] . MIC1 contains a tandemly duplicated domain that is distantly related to the thrombospondin -1-like domain of thrombospondin-related anonymous protein and that specificall binds lactose [10] . MIC3 contains several epidermal growth factorlike domains and a lectin-like domain that is required for binding [11] . Both MIC1 and MIC3 assemble with other MICs into independent complexes, MIC1/4/6 and MIC3/8. MIC1 is absolutely required for the MIC1/4/6 complex to leave the early compartments of the secretory pathway [12] ; thus, disruption of the mic1 gene alone corresponds to a functionally triple-KO parasite. Disruption of either the mic1 gene or the mic3 gene causes slightly reduced virulence in mice, and the double-KO (Mic1-3KO) form is markedly impaired in virulence [13] . Furthermore, Mic1-3KO parasites have been shown to protect male OF1 mice against oral cyst challenge, which is the natural route of infection for acquired toxoplasmosis.
We vaccinated female OF1 mice with Mic1-3KO tachyzoites and evaluated the vaccine's efficac against chronic and congenital toxoplasmosis. Our data show that OF1 mice (both virgins and dams) vaccinated with Mic1-3KO were highly protected against an oral challenge with T. gondii cysts and that this vaccine conferred highly significan protection against congenital toxoplasmosis. This protection was associated with a strong humoral and a potent Th1 cellular immune response.
MATERIALS AND METHODS
Mice. Eight-week-old male and female outbred Swiss OF1 mice and 8-week-old female inbred CBA/J mice were obtained from Janvier. All experiments were performed in accordance with the Tours University guidelines for animal experimentation.
Parasites. RH strain tachyzoites were maintained by serial ip passage in Swiss OF1 mice, and these were used to prepare T. gondii antigen (TAg) as described elsewhere [14] . Type II strain 76K cysts were obtained from the brains of orally infected CBA/J mice, were maintained by monthly passage, and were used for oral challenge. Type II isolates are predominant in human and sheep congenital toxoplasmosis [15, 16] . Mic1-3KO tachyzoites were obtained by targeted gene disruption of the mic1 and mic3 genes in the DHX RH strain of T. gondii [13] and were used for vaccination. Mic1-3KO tachyzoites were maintained by serial passage in primary human foreskin fib oblasts grown in Dulbecco's modifie Eagle medium supplemented with 10% fetal calf serum, 2 mmol/L l-glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin.
Mouse vaccination. Female OF1 mice were vaccinated once ip with 20 Mic1-3KO tachyzoites that had been freshly harvested from cell cultures, using syringes with 26-gauge needles (Microlance; Becton Dickinson). Outbred mice were used to circumvent any genetic restriction of protection.
Humoral response. Titers of antigen-specifi IgG antibodies in serum samples obtained from vaccinated mice were determined by an ELISA using TAg, as described elsewhere [14] . The antigen-specifi antibody titer is given as the reciprocal of the highest dilution whose absorbance was 2.5-fold greater than the absorbance of the serum of untreated mice at the same dilution. Results are expressed as the mean ‫ע‬ SD of log 2 titers.
Cytokine production. Spleen cells were prepared as described elsewhere [14] . Cells were stimulated with 5 mg/mL of TAg or medium alone. Cell-free supernatants were harvested and assayed for interleukin (IL)-2 and IL-4 activity after 24 h, for IL-10 activity after 72 h, and for IFN-g activity after 96 h. Concentrations of IL-2, IL-4, IL-10, and IFN-g were determined by ELISA (OptEIA Set; Pharmingen), in accordance with the manufacturer's instructions.
Evaluation of protection against acquired chronic toxoplasmosis in virgins and dams.
Female Swiss OF1 mice, either vaccinated with Mic1-3KO tachyzoites or untreated, were orally challenged on day 71 (which corresponded to day 11 of gestation for pregnant mice) with 45 cysts of T. gondii strain 76K. Protection was evaluated 1 month after challenge by analyzing the cyst load in brain tissue. Mouse brains were homogenized in 5 mL of PBS, and the number of tissue cysts per brain was analyzed by counting 12 samples (10 mL each) of each homogenate under the microscope. When cysts were not found in brain tissue by counting, a bioassay for viable T. gondii cysts was performed. After centrifugation at 2000 g for 5 min, brain tissue was resuspended in 1 mL of RPMI 1640 and administered orally (2 doses of 0.5 mL each) to uninfected recipient Swiss OF1 mice (an entire brain-tissue sample to a single recipient mouse). Six weeks later, blood samples were obtained from the retro-orbital plexus, and serum was assayed for the presence of anti-Toxoplasma IgG by ELISA.
Evaluation of protection against congenital toxoplasmosis. Female OF1 mice vaccinated with Mic1-3KO were mated with males on day 60. Females were placed in a male's bedding for 48 h, to synchronize estrus, and were then caged with males (ratio, 1:3) for 72 h. Pregnant females were infected orally on day 11 of gestation with 45 cysts of strain 76K. The 2 control groups were nonvaccinated infected mice (oral infection on day 11 of gestation) and nonvaccinated uninfected mice. On day 17 of gestation, 4 vaccinated infected pregnant females and 
NOTE.
The presence or absence of T. gondii infection was assessed in fetuses before delivery, on day 17 of gestation (day 6 of infection). Fetuses from nonvaccinated infected mice (3 litters, 33 fetuses) and from vaccinated infected mice (4 litters, 43 fetuses) were homogenized separately in PBS, then inoculated intraperitoneally into recipient OF1 mice, to ascertain whether the fetuses were infected. Six weeks later, blood samples were obtained from the retro-orbital plexus, and serum was assayed for the presence of Toxoplasma antibody using ELISA. The no. of positive fetuses corresponds to the no. of mice positive according to ELISA for the presence of Toxoplasma antibody. a . P p .001 Figure 2 . Survival and body weight of neonates born to Swiss OF1 mice vaccinated with 20 Mic1-3KO tachyzoites, then infected orally with 45 strain 76K cysts on day 11 of gestation (vaccinated infected). Neonates born to nonvaccinated uninfected mice and to nonvaccinated mice infected orally with 45 strain 76K cysts were used as controls. Neonate survival was monitored for 35 days (A), and pups were weighed when they were 11 days old (B).
3 nonvaccinated infected pregnant mice were killed and tested for congenital infection in utero. Fetuses were delivered via transabdominal incision under sterile conditions. Fetal tissues were homogenized in 3 mL of PBS that contained penicillin (100 U/mL) and streptomycin (100 mg/mL; PBS + P/S) and then filte ed through nylon mesh. After centrifugation at 2000 g for 5 min, fetal tissues were resuspended in 0.5 mL of PBS + P/S and inoculated ip into uninfected recipient mice (1 fetus/ 1 recipient mouse). Six weeks later, blood samples were obtained from the retro-orbital plexus. Serum samples were tested for Toxoplasma antibody IgG by ELISA. Naturally delivered pups were evaluated for protection against congenital infection by analyzing survival from day 1 to day 35 of age, weight on day 11 of age, and cyst load in brain tissue on day 35 of age.
Statistical analysis. Levels of significanc of the differences between groups of mice were determined using the MannWhitney U test, the Mann-Whitney exact test (when applicable), or Fisher's exact test (for maternofetal transmission and complete protection).
RESULTS

Immune Responses after Vaccination
By 23 days after vaccination with 20 Mic1-3KO tachyzoites, vaccinated female mice had seroconverted (experiment 1, n p 14; experiment 2, ). Antibody titers were measured n p 15 by ELISA using TAg: the anti-T. gondii IgG titers were 12 ‫ע‬ in experiment 1 and in experiment 2. These results 2 1 5 ‫ע‬ 7 indicated that Mic1-3KO induced a strong humoral response.
Cytokine production by TAg-stimulated splenocytes demonstrated that vaccination potentiated a strong Th1 immune response as measured by IFN-g production. Supernatants from restimulated splenocyte cultures from 8 vaccinated OF1 mice contained more IFN-g ( ng/mL) than supernatants 285 ‫ע‬ 125 
860 ‫ע‬ 173 Brain homogenates from the experimental mice (vaccinated and infected but !40 brain cysts detected) were subsequently administered orally to uninfected recipient mice, to test whether the experimental mice had developed any cysts capable of causing reinfection. Anti-T. gondii IgG was produced by 1 of 7 (experiment 1) and 5 of 7 (experiment 2) mice, which indicates that some cysts had developed in vaccinated infected mice. Complete protection efficac was 85.7% (6/7 mice; significan at P p .015) in experiment 1 and 28.5% (2/7 mice; not significant in experiment 2. The difference in the number of cysts in brain tissue was statistically significan in both experiments (experiment 1, ; experiment 2, ). P p .0012 P p .0025
Protection against Congenital Toxoplasmosis
No abortions were observed in vaccinated mice. Survival of neonates. Neonate survival was 100% for mice vaccinated with Mic1-3KO and then infected orally with strain 76K on day 11 of gestation in both experiments (figu e 2). All neonates born to vaccinated infected mice in experiment 1 (n p 14) and experiment 2 ( ) survived until the end of n p 15 the experiments (day 35 of age). In the control groups, litters born to nonvaccinated infected mice had lower survival (60% in experiment 1 and 64% in experiment 2).
Mean weight of pups. Live pups were weighed when they were 11 days old (figu e 2). Pups born to experimental mice (vaccinated and then infected orally with strain 76K cysts on day 11 of gestation) weighed more (experiment 1, 5.8 ‫ע‬ 0.25 g; experiment 2, g) than pups born to control mice 5 ‫ע‬ 0.5 (nonvaccinated infected; experiment 1, g; experi-3.2 ‫ע‬ 0.95 ment 2, g). The difference in weight was statistically 2.7 ‫ע‬ 1.1 significan in both experiments ( ). The mean weight of P ! .001 pups born to vaccinated infected mice was similar to that of pups born to nonvaccinated uninfected mice (experiment 1, g; experiment 2, g). 5.32 ‫ע‬ 0.58 5 ‫ע‬ 0.9 Cyst load in brain tissue. On day 35 after birth, pups were killed, and the number of cyst in brain tissue was analyzed (table 3) . Each brain was homogenized in 3 mL of PBS. Brain cysts were counted under the microscope. Tissue cysts were detected in all pups ( ) born to nonvaccinated infected n p 53 mice ( ; per brain). Forty-fiv percent of pups n p 7 618 ‫ע‬ 557 ( ) born to vaccinated infected mice ( ) had 56 n p 71 n p 14 ‫ע‬ 34 cysts per brain (91% reduction). The difference in the number of cysts in brain tissue was statistically significan ( ). No cysts were detected in 55% of other pups (n P ! .0001 p 86), which indicates that these pups had !25 cysts per brain (196% reduction).
Cytokine Production after Infection during Pregnancy
We investigated cytokine production by maternal spleen cells on day 17 of gestation (day 6 of infection) (figu e 3). IFN-g and IL-2 production was much higher in TAg-stimulated splenocytes from vaccinated infected mice than in those from nonvaccinated uninfected mice. Stimulated splenocytes from nonvaccinated infected mice did not produce significan levels of IFN-g and IL-2, compared with those from nonvaccinated un- Figure 3 . Cytokine production by splenocytes from mice vaccinated and infected orally with 45 strain 76K cysts on day 11 of gestation. Splenocytes were recovered on day 6 of infection and stimulated in vitro with Toxoplasma gondii antigen (5 mg/mL). Cell-free supernatants were harvested and assayed for interleukin (IL)-2 and IL-4 activity after 24 h, for IL-10 activity after 72 h, and for interferon (IFN)-g activity after 96 h. Nonvaccinated uninfected mice and nonvaccinated mice infected orally with 45 strain 76K cysts on day 11 of gestation were used as controls.
for IFN-g, IL-P ! .03 2, and IL-10;
for IL-4 (vs. nonvaccinated uninfected mice). P ! .1 infected mice. We found no specifi release of IL-4 in any culture supernatant. However, as demonstrated in virgin mice 2 months after vaccination (figu e 1), some IL-10 was secreted into the supernatants of restimulated splenocyte cultures from vaccinated and infected mice. No specifi release of IL-10 was observed in cells from nonvaccinated mice.
Cyst Load in Brain Tissue of Mice 1 Month after Delivery
The cyst load in brain tissue was evaluated in dams ∼1 month after delivery (table 4) . Vaccinated female mice were orally challenged with 45 strain 76K cysts on day 71 (day 11 of gestation). In experiment 1, 10 vaccinated dams had !40 tissue cysts, and 4 dams had 40 tissue cysts; this corresponds to a 97.7% reduction in the number of cysts with reference to nonvaccinated infected dams ( cysts, ). Brain ho-1798 ‫ע‬ 1139 n p 7 mogenates were then bioassayed in nonvaccinated uninfected recipient mice; 5 brain homogenates contained cysts. In experiment 2, all vaccinated dams had !40 cysts in tissue (n p ), a 96.7% reduction in the number of cysts with reference 15 to nonvaccinated infected dams ( cysts, ). 1205 ‫ע‬ 846 n p 14 When bioassayed, 14 brain homogenates contained cysts. The efficac of complete protection was 35.7% (5/14 mice) in experiment 1 and 6.6% (1/15 mice) in experiment 2 (not significan in both experiments). The difference in numbers of cysts in brain tissue was statistically significan in both experiments ( ). P ! .0001
DISCUSSION
At present, only 1 vaccine against toxoplasmosis has been licensed, and this vaccine uses a strain that has no ability to induce chronic infection. The possibility that live vaccines may revert to more-virulent forms gives impetus to the development of safer strains by the disruption of virulent genes.
Congenital infection occurs only when mothers firs encounter T. gondii during pregnancy. Resistance to T. gondii is mainly mediated by Th1 cytokines, particularly IFN-g and IL-2. Susceptibility of the pregnant host to toxoplasmosis may be due to a Th2 cytokine bias that is maintained during gestation [17, 18] . Pregnant mice are more susceptible to infection with T. gondii and have higher mortality than similarly infected nonpregnant female mice [17, 19] . This increased susceptibility of pregnant mice to T. gondii infection is associated with reduced Th1 function, as demonstrated by a decrease in the capacity to produce IFN-g [20] . Furthermore, the survival of pregnant mice infected with T. gondii has been shown to be improved by the administration of Th1 cytokines, such as IFN-g and IL-2 [20] . The immune response of mice to T. gondii during pregnancy has also been studied using transgenic IL-4-deficien BALB/c mice. Pregnant wild-type mice are more susceptible than IL-4-deficien mice to toxoplasmosis, and they have higher parasite loads. Pregnant IL-4-deficien mice have also demonstrated a lower transmission rate to fetuses than wild-type mice [18] . However, although pregnant C57BL/6 ϫ 129SV IL-4-deficien mice were more resistant to T. gondii infection than were wild-type controls, no reduction in fetal transmission was seen in these mice [21] . Effects from the genetic background of the mice may account for these apparently contradictory results.
The immune response generated by Mic1-3KO vaccination was clearly a Th1 response. Measurements of the cyst burden in the brain showed that the response effectively protected against adult acquired T. gondii infection after oral challenge with cysts of strain 76K type II.
Mice were mated 2 months after vaccination with Mic1-3KO, because reproductive failure was observed when mice were mated earlier (e.g., 1 month after vaccination; data not shown). It is possible that an ongoing anti-parasite Th1 response adversely affects both implantation and maintenance of the placenta, as reported by Krishnan et al. [22] in C57BL/6 mice infected with Leishmania major. Infection of C57BL/6 mice infected with L. major normally results only in a minor selfhealing lesion at the site of inoculation and full recovery of the mouse mediated by a strong Th1 response. When C57BL/6 mice were infected with L. major at intervals before and during pregnancy, the frequency of implantation failure and fetal resorption (abortions) clearly increased. Unlike C57BL/6 mice, BALB/c mice infected with L. major showed a Th2 cytokine pattern with a resultant progressive infection and, ultimately, death; however, and again unlike C57BL/6 mice, BALB/c mice did not have lower implantation rates.
The Mic1-3KO vaccination reduced the rate of maternofetal transmission of toxoplasmosis. Pregnant vaccinated mice showed a Th1 cytokine pattern after challenge, 6 days after infection. This is similar to the cytokine pattern seen 2 months after vaccination, before challenge, in virgin mice. In both pregnant vaccinated mice that were then challenged and virgin vaccinated mice, IL-10 was produced without a significan production of IL-4. This suggests that the protective Th1 immune response induced by vaccination is balanced during pregnancy. Indeed, a Th1-induced immune response before gestation is important for the prevention of congenital transmission. Long and Baszler [23] showed that modulation of the cytokine response in naive mice during gestation does little to change the frequency of congenital protozoal transmission (Neospora caninum), whereas the manipulation of antigen-specifi maternal immune responses before gestation changes the susceptibility of dams to congenital transmission. In particular, the downregulation of the Th2 antigen-specifi immune response before gestation results in a significan decrease in congenital transmission after challenge infection during gestation. However, as described above, the Th1 immune response may be a cause of immune-mediated failure of pregnancy, and modulation of the Th1 response may underlie the delicate balance between the maintenance of pregnancy and resistance to the parasite. During pregnancy, on day 17 of gestation, only 33% of the fetuses in control nonvaccinated mice showed signs of infection; however, by 35 days after birth, all pups in this group were infected. This may have been due to in utero transmission at the end of gestation or during delivery or, possibly, to transmission via lactation [24] [25] [26] . However, we did not test this by placing the pups with foster mothers to prevent possible infection via lactation, and we showed that OF1 dams developed enough immunity to protect their pups. Indeed, all pups born to vaccinated dams survived (only 60.05% of pups born to control nonvaccinated dams survived); they did not weigh less than pups born to naive mice, and there were significantl fewer cysts in their brains than in those from pups born to nonvaccinated mice (brain cysts were not detected in 55% of pups born to vaccinated dams). Further analyses are needed to ascertain whether these pups are infected. Serum samples were collected from 5 litters of pups born to vaccinated dams (n p 57 pups) before the pups were killed. Anti-T. gondii antibodies were not detected by ELISA in 11 pups (19%), which indicates that these pups were not infected.
A significantl smaller number of cysts in brain tissue was seen in vaccinated dams and in virgin mice than in nonvaccinated dams ∼1 month after birth (196% cyst reduction). Pregnant OF1 mice were not more susceptible to chronic infection than nonpregnant mice. No significan difference was seen between the 2 groups in their cyst load in brain tissue. Increased susceptibility to chronic infection has been reported in BALB/c mice [18] and in CBA/J mice (C. Beauvillain, INSERM U564, Angers, France, personal communication).
In conclusion, the present results demonstrate, to our knowledge for the firs time, that Mic1-3KO is a potent, effective, and successful vaccine against toxoplasmosis because it provides highly significan protection against acquired and congenital T. gondii infection in female OF1 mice. This protection was associated with strong and specifi humoral and cellular immune responses in adult mice. In addition, our model constitutes an attractive experimental model for the development of vaccines that may overcome the drawbacks of the existing S48 vaccine. This vaccine has to be evaluated in relevant animals, such as sheep.
